Gland Pharma gets USFDA Approval
- Sugammadex is a medication for the reversal of neuromuscular blockade induced by rocuronium and vecuronium in general anesthesia.
- It is the first selective relaxant binding agent (SRBA).
- In the European Union, sugammadex is indicated for the reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults.
- Sugammadex is a modified γ-cyclodextrin, with a lipophilic core and a hydrophilic periphery.
- Gland Pharma has received tentative approval from the United States Food and Drug Administration (US FDA) for Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vial.
Sugammadex Injection is used to reverse the effects of the muscle relaxants Rocuronium Bromide and Vecuronium Bromide given to patients during surgery. The company will launch the product through its marketing partner on receipt of final approval. The Sugammadex Injection, 200 mg/2 mL and 500 mg/5 mL Single-Dose Vial (RLD: Bridion) has US sales of approximately USD 615 million for twelve months ending in April 2021, according to IQVIA.
In the European Union, sugammadex is indicated for the reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. Sugammadex is only recommended for routine reversal of rocuronium-induced blockade in children and adolescents
At around 12.53 pm, Gland Pharma was trading at Rs3841.75 per piece down by Rs9.80 or 0.3% on Sensex. The stock has touched an intraday high and low of Rs3909.95 per piece and Rs3822.05 per piece respectively.
Pharmacodynamics:
Sugammadex is a modified γ-cyclodextrin, with a lipophilic core and a hydrophilic periphery. This gamma-cyclodextrin has been modified from its natural state by placing eight carboxyl thioether groups at the sixth carbon position. These extensions extend the cavity size allowing greater encapsulation of the rocuronium molecule. These negatively charged extensions electrostatically bind to the quaternary nitrogen of the target as well as contribute to the aqueous nature of the cyclodextrin.
Sugammadex’s binding encapsulation of rocuronium is one of the strongest among cyclodextrins and their guest molecules. Sugammadex, unlike neostigmine, does not inhibit acetylcholinesterase so cholinergic effects are not produced and co-administration of an antimuscarinic agent (glycopyrronium bromide or atropine) is not needed. Sugammadex might therefore be expected to have fewer adverse effects than the traditional reversal agents.
When muscle relaxant with rapid onset and short duration of action is required, there has been little choice apart from succinylcholine but this drug has important contraindications; for example, it can trigger malignant hyperthermia in susceptible individuals, it has a prolonged duration of action in patients with pseudocholinesterase deficiency and it causes an increase in plasma potassium concentration which is dangerous in some circumstances. Rocuronium has a comparably quick onset in high doses (0.6 mg kg−1 to 1 mg kg−1) and can be rapidly reversed with sugammadex (16 mg kg−1), so this drug combination offers an alternative to suxamethonium.
Efficacy:
The study was carried out in Europe looking at its suitability in rapid sequence induction. It found that sugammadex provides a rapid and dose-dependent reversal of neuromuscular blockade induced by high-dose rocuronium.
A Cochrane review on sugammadex concluded that “sugammadex was shown to be more effective than placebo (no medication) or neostigmine in reversing muscle relaxation caused by neuromuscular blockade during surgery and is relatively safe. Serious complications occurred in less than 1% of the patients who received sugammadex. The results of this review article (especially the safety results) need to be confirmed by future trials on larger patient populations”. The 2017 Cochrane review concluded that sugammadex has a better safety profile than neostigmine with 40% fewer adverse events. Specifically, the risks of postoperative residual paralysis, bradycardia, nausea and vomiting are reduced if sugammadex is used as a reversal agent.
The British Journal of Anaesthesia published an article in 2015 in which the incidence of the residual neuromuscular blockade could be reduced to zero if sugammadex is used as the reversal agent and the correct dosage is selected with the use of neuromuscular monitoring. Also when the reversal times of each agent were compared “Data indicate that sugammadex was 10.22 minutes (6.6 times) faster than neostigmine (1.96 vs 12.87 minutes) in reversing moderate induced paralysis. Sugammadex was 45.78 minutes (16.8 times) faster than neostigmine (2.9 vs 48.8 minutes) in reversing deep induced paralysis.” The time saved by rapid reversal and the reduction of postoperative residual paralysis may reduce the overall hospital costs and provide significant improvements in patient safety.
Tolerability
Sugammadex was generally well tolerated in clinical trials in surgical patients or healthy volunteers. In pooled analyses, the tolerability profile of sugammadex was generally similar to that of placebo or neostigmine plus glycopyrrolate.
Sugammadex may theoretically interfere with hormonal contraceptives due to evidence from in vitro binding studies which showed it may bind to progestogen
History:
Sugammadex was discovered by the pharmaceutical company Organon at the Newhouse Research Site in Scotland. Organon was acquired by Schering-Plough in 2007; Schering-Plough merged with Merck in 2009. Sugammadex is now owned and sold by Merck.
The US Food and Drug Administration (FDA) initially rejected Schering-Plough’s New Drug Application for sugammadex in 2008, but finally approved the medication for use in the United States in December 2015.
Sugammadex was approved for use in the European Union in July 2008.
Treatment Reactions:
The most commonly reported sugammadex side effects may include:
- Vomitin
- Pain
- Nausea
- Hypotension
- Headache
Warnings and Precautions:
- The sugammadex dose for reversal should not be given if you are allergic to it or any of its other ingredients.
- The use of this medication is not recommended for infants aged less than 2 years.
- Talk to your anaesthetist before sugammadex uses, inform your anaesthetist if you have had kidney disease, liver disease, fluid retention and increased risk of bleeding. Inform your anaesthetist in case you are taking, have recently taken or might take any other drugs. The sugammadex 200 mg may be responsible for affecting other drugs or be affected by them.
- It is crucial that you inform your anaesthetist in case you’ve recently taken toremifene (used to treat breast cancer) and fusidic acid (an antibiotic).
- Prior to starting treatment with bridion 200mg injection, inform your anesthetist in case you’re pregnant or might be pregnant or if you are breast-feeding.
For more Information: Sign-in Websites for Agrochemical & Pharmaceutical Databases:
- Website: https://www.chemrobotics.com/ (Agrochemical Databases)
- Website: https://chemroboticspharma.com/ (Pharmaceutical Databases)